Using Pronase to Improve Mucosal Cleanliness During EGD

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study investigates the effect of premedication with pronase and dimethicone on mucosal cleanliness during esophagogastroduodenoscopy (EGD) in patients with esophageal and gastric cancer. It aims to determine whether adding postural exercises enhances the effectiveness of these medications in improving visibility during the procedure. The study will compare different intervention groups to assess the impact on mucosal cleanliness and the potential for better detection of lesions. The findings could provide insights into optimizing EGD procedures for better diagnostic outcomes.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Male or female aged ≥18 years and ≤70 years;
2. Voluntarily participate in the trial and sign the informed consent.

Exclusion Criteria:

1. active gastrointestinal bleeding;
2. esophageal stricture, complete pyloric obstruction and gastroparesis caused by various reasons;
3. diagnosed malignant tumors of the upper digestive tract;
4. a history of upper gastrointestinal surgery;
5. severe heart, liver and kidney diseases, and the doctor judges that it is not suitable for painless gastroscopy;
6. serious mental illness;
7. pregnancy or breastfeeding;
8. an allergy to pronase or dimeticone;
9. current participation in other clinical trials and in the follow-up or drug washout period;
10. patients considered by the investigator to be unsuitable for this study

Where it's running

• Changhai hosipital
  Shanghai, China Recruiting

Study contacts

• Principal investigator: Luowei Wang, MD — Changhai hosipital, Shanghai
• Study coordinator: Luowei Wang, MD
• Email: wangluoweimd@126.com
• Phone: 13901833088

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Adding 2141-V11 to standard therapy for advanced esophageal, gastric, or gastroesophageal junction cancer

  This study tests whether adding the drug 2141-V11 to standard anti-PD-1 therapy (with or without 5-FU) is safe for adults with advanced or metastatic esophageal, gastric, or gastroesophageal junction adenocarcinoma.

  Recruiting at 7 sites Phase 1/2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07818018

• First-in-human STRO-006 in adults with certain recurrent or metastatic solid tumors

  This study tests STRO-006 alone and with pembrolizumab in adults with certain head and neck, lung, esophageal, gastric, colorectal cancers to see if it is safe and shows early anticancer activity.

  Recruiting at 3 sites Phase 1 Sutro Biopharma, Inc. · Orlando, Florida and 5 other locations · NCT07807345

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• Molecular comparison of primary gastroesophageal cancers and their brain metastases

  This project will test whether key biomarkers (HER2, MSI, PD-L1, CLDN18.2) match between primary gastroesophageal tumors and their matched brain metastases using archived tissue.

  Recruiting Blokhin's Russian Cancer Research Center · Moscow · NCT07464470

• Sonesitatug vedotin plus capecitabine, with or without rilvegostomig, for CLDN18.2-positive advanced gastric, gastroesophageal junction, or esophageal adenocarcinoma

  This trial will test whether adding sonesitatug vedotin to capecitabine, with or without rilvegostomig, helps people with untreated CLDN18.2-positive, HER2-negative advanced or metastatic gastric, GEJ, or esophageal adenocarcinoma.

  Recruiting at 158 sites Phase 3 AstraZeneca · Birmingham, Alabama and 313 other locations · NCT07431281

• PET imaging that targets CLDN18.2 to find stomach, pancreatic, bile-duct, and esophageal cancers

  This project will try a CLDN18.2-targeted PET scan in adults with suspected or confirmed gastric, pancreatic, bile-duct, or esophageal cancer (and some healthy volunteers) to see if it can show CLDN18.2-positive tumors.

  Recruiting Union Hospital, Tongji Medical College, Huazhong University of Science and Technology · Wuhan, Hubei · NCT07301814

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.